Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
Mikkelsen MK, Lund CM, Vinther A, Tolver A, Johansen JS, Chen I, Ragle AM, Zerahn B, Engell-Noerregaard L, Larsen FO, Theile S, Nielsen DL, Jarden M. Mikkelsen MK, et al. Among authors: johansen js. Oncologist. 2022 Feb 3;27(1):67-78. doi: 10.1002/onco.13970. Oncologist. 2022. PMID: 34498352 Free PMC article. Clinical Trial.
Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Johansen JS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202. doi: 10.1158/1055-9965.EPI-05-0011. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492905 Review.
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH. Svane IM, et al. Among authors: johansen js. Cancer Immunol Immunother. 2007 Sep;56(9):1485-99. doi: 10.1007/s00262-007-0293-4. Epub 2007 Feb 7. Cancer Immunol Immunother. 2007. PMID: 17285289 Free PMC article. Clinical Trial.
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Høgdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhøffer M, Johansen JS. Schou JV, et al. Among authors: johansen js. PLoS One. 2014 Jun 18;9(6):e99886. doi: 10.1371/journal.pone.0099886. eCollection 2014. PLoS One. 2014. PMID: 24940606 Free PMC article. Clinical Trial.
Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL, Pallisgaard N, Appelt AL, Andersen RF, Schou JV, Nielsen D, Pfeiffer P, Yilmaz M, Johansen JS, Hoegdall EV, Jakobsen A, Jensen BV. Spindler KL, et al. Among authors: johansen js. Eur J Cancer. 2015 Nov;51(17):2678-85. doi: 10.1016/j.ejca.2015.06.118. Epub 2015 Oct 24. Eur J Cancer. 2015. PMID: 26508156 Clinical Trial.
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, Jensen BV, Hansen TF, Sefrioui D, Andersen RF, Brandslund I, Jakobsen A. Spindler KG, et al. Among authors: johansen js. Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4. Oncologist. 2017. PMID: 28778958 Free PMC article. Review.
Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.
Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Chen I, et al. Among authors: johansen js. Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228650 Free PMC article.
309 results